2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Coagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thrombotic Disorders, VWD, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric
PAPER

4817 Beyond the bleeding score: Evaluating the incremental value of family history in ISTH-BAT

Maria Carter Febres, MD, Lori Luchtman-Jones, MD2
1 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital, Cincinnati, Ohio, United States

A bleeding history is a crucial component of the evaluation for suspected bleeding disorders to guide testing and diagnosis. Scores for the standardized International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT) can be used to quantify bleeding symptoms and guide laboratory testing in adults and children with suspected mild bleeding disorders (MBD), so that extensive (and expensive) testing is reserved for those with a higher bleeding score, i.e. a higher likelihood of a bleeding disorder. [1, 2] A major limitation of bleeding assessment tools is that younger patients may not yet have had exposure to hemostatic challenges. The purpose of this project was to evaluate the predictive value of adding 2 family history questions to the ISTH-BAT.  Our overarching hypothesis was that the addition of family history questions (BAT+) will improve the negative and positive predictive value of the ISTH-BAT for presence of a MBD in patients between 0-21 years of age who have been newly referred to pediatric hematology clinic for concern of a bleeding disorder, focusing on cohorts of patients <5, 5-8, 8-18, >18 years of age. Methods: A retrospective review of the clinical and laboratory data by electronic health record review of all individuals seen at Cincinnati Children’s Health Medical Center (CCHMC), Center for Bleeding and Clotting Disorders (CBDI) clinic with a reported BAT and BAT+ score from January 2019, through December 1, 2024, identified via an Epic data pull. The added exploratory family history questions ask about the presence of a first degree relative with a bleeding disorder (yes = 1 point) or first- or second-degree relatives with any of a list of bleeding symptoms (yes = 1 point for each symptom). Results: Over 6 years, among individuals age 0-21 years, 2840 individuals were seen for a new visit to be evaluated for a bleeding disorder. A total of 2116 had a BAT/BAT+ assessment and were evaluable. Median age at first clinic visit was 10.6 years (4.9 - 15.3). Four age groups were analyzed: <5 years 534 (25.2%), 5-8 years 302 (14.3%), 8-18 years 1133 (53.5%) and >18-21 years 147 (6.9%). Biologic females represented a slight majority (1254, 59.3%). The median BAT score for the overall cohort was 2.0 (0.0, 3.0), and the median BAT+ was 3.0 (2.0, 5.0). Using a threshold score of 3 for BAT as predictor of MBD in pediatrics, a threshold of 4 for the BAT+ was selected because its NPV for the whole group was close to that of the BAT for threshold of 3. For MBD, the AUC was 0.556 for BAT and 0.587 for BAT+; at the optimal thresholds, sensitivity increased from 44.0% to 55.6%, while specificity decreased from 65.4% to 60.0%. For von Willebrand disease, AUC increased from 0.548 to 0.585 and sensitivity from 27.5% to 42.0%. Neither BAT nor BAT+ discriminated against factor deficiency (excluding FVIII and FIX) (AUC 0.463 vs. 0.490). In contrast, both tools demonstrated moderate discrimination for platelet dysfunction (AUC 0.717 vs. 0.715), with no incremental benefit from family history. The addition of family history did not preferentially improve discrimination among children <8 years. Conclusion: In this large pediatric hematology referral cohort, the diagnostic performance of the BAT varied substantially by underlying bleeding disorder. Addition of family history questions modestly improved sensitivity and discrimination for MBDs overall and vWD but did not improve discrimination for platelet dysfunction or factor deficiencies. The benefit of our family history questions was not greater among children younger than 8 years. Bleeding assessment tools demonstrated moderate discrimination for platelet dysfunction but poor discrimination for vWD and factor deficiencies. The lack of a stronger association may in part reflect the structure of the family history variable. Because the current scoring system captures family history largely as a binary feature, it does not distinguish between one versus multiple affected relatives. Families with substantial clustering of a given bleeding phenotype may be assigned the same score as families with only a single affected relative, attenuating their association with bleeding severity.

Maria Carter Febres, MD: No relevant conflicts of interest to declare.